Capstone Nutrition Wins Settlement in MusclePharm Litigation

Ogden, Utah, November 8, 2016

Capstone Nutrition (“Capstone”) today confirmed that it has reached a favorable settlement agreement with MusclePharm Corporation (“MusclePharm”) following a complaint filed on May 16, 2016 against MusclePharm for multiple contract breaches, including failing to pay for product received and failing to meet minimum volume requirements.

As part of the settlement, Capstone will receive an undisclosed amount of cash and other consideration from MusclePharm, as well as MusclePharm’s dismissal with prejudice of its counter-complaint filed on June 21, 2016.

“Capstone has seen dramatic customer growth and confidence since moving on from the MusclePharm relationship last year, and we are pleased now to have reached such a satisfactory settlement, thereby ending the MusclePharm chapter,” said Jared Leishman, Capstone’s Chief Executive Officer. “These positive results, together with our owners’ continued strong financial backing, bolster Capstone’s position as the premier manufacturing partner for the nutrition and sports supplement industry.”

For media inquiries, please contact Liz Bruce at Fitzroy Communications: 212.498.9197 or lb@fitzroypr.com.

About Capstone Nutrition

Capstone Nutrition is the leading pure-play, turnkey developer and manufacturer of high quality nutrition products. Capstone provides a one-stop shop for innovators in nutrition. Since 1992, Capstone has been developing, producing and packaging a wide range of capsule, tablet and powder products for a variety of customers in the United States and internationally. Capstone is well known for its exceptional quality and maintains several industry certifications recognizing its high manufacturing standards, including NSF GMP, NSF for Sport and Australia’s Therapeutic Goods Administration (“TGA”) certification. For more information, please visit www.CapstoneNutrition.com.